Signature Estate & Investment Advisors LLC Sells 32,625 Shares of Becton, Dickinson and Company $BDX

Signature Estate & Investment Advisors LLC lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 94.2% in the 2nd quarter, Holdings Channel reports. The firm owned 2,017 shares of the medical instruments supplier’s stock after selling 32,625 shares during the quarter. Signature Estate & Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $347,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Saudi Central Bank bought a new stake in Becton, Dickinson and Company in the first quarter worth about $26,000. Smallwood Wealth Investment Management LLC bought a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $27,000. Alpine Bank Wealth Management bought a new position in Becton, Dickinson and Company in the first quarter worth approximately $29,000. Cornerstone Planning Group LLC raised its stake in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new position in Becton, Dickinson and Company in the first quarter worth $31,000. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $191.28 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10. The stock has a market capitalization of $54.83 billion, a P/E ratio of 34.40, a PEG ratio of 1.48 and a beta of 0.25. The company has a 50 day moving average price of $190.58 and a 200 day moving average price of $184.25. Becton, Dickinson and Company has a fifty-two week low of $163.33 and a fifty-two week high of $251.99.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Equities research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at $4,167,375. This trade represents a 3.96% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last three months, insiders have sold 1,838 shares of company stock worth $348,392. Company insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on BDX shares. Morgan Stanley boosted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Piper Sandler restated a “neutral” rating and set a $200.00 target price (up from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Argus raised their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Royal Bank Of Canada restated a “sector perform” rating and set a $211.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, October 16th. Finally, Wells Fargo & Company upped their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.